clinical trial · NCT06834399
TATE and KN046 in MCRC
Zhejiang Raygene Pharmaceuticals Co., Ltd·phase2·terminated·n = 42
Colorectal Cancer with Hepatic MetastasesKN046 （PD-L1/CTLA4 BsAb）TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
brief summary
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc fusion protein injection) in patients with liver metastases from colorectal cancer.
started
Apr 27, 2023
primary completion
Dec 17, 2024
completion
Jan 9, 2025
last updated
Feb 19, 2025
official title
Phase IIA Clinical Trial of Intra-arterial Administration of Tirapazamine Followed by Transarterial Embolization （TATE）and KN046 for the Treatment of Advanced Colorectal Cancer with Liver Metastasis (MSS/pMMR)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol